Clinical evidence
Heli-FX™ EndoAnchor™ system
Review the results of clinical studies and trials related to the effectiveness of the Heli-FX™ EndoAnchor™ system.
Wide neck cohort (n = 72)
(N = 6,602 f/u ranged from 2.7 years [mean] to 3.9 years)
ESAR reinforces and protects the proximal seal, leading to better outcomes in wide necks. View data on wide necks from literature compared to the three-year wide neck results from the ANCHOR Registry.
(Wide necks ≥ 28 mm and ≤ 32 mm mean neck diameter 29.5 mm)
Hear from Professor Michel Reijnen on the importance of the ANCHOR three-year wide neck data. (03:33)
Dr. William Jordan Jr. discusses the ANCHOR Registry and how it captures real-world usage and long-term outcomes of EndoAnchor™ implant fixation in EVAR. (01:10)
Primary AAA arm (n = 771)4
Learn about the ANCHOR Registry design methods, results, and proven durability of ESAR with the Heli-FX™ EndoAnchor™ system in challenging AAA patients. (02:21)
| ANCHOR primary AAA arm | N = 771 |
|---|---|
| Female | 21.3% |
| Average age | 73.5 years |
| Hostile necks | 88.7% (572/645) |
| ASA Class III/IV | 87.8% (674/768) |
| Urgent or emergent | 17.9% (119/664) |
| ANCHOR primary AAA arm | N = 771 |
|---|---|
| Technical success9 | 98.8% (738/747) |
| Average time to place EndoAnchor™ implants | 19.6 min |
| Average number of EndoAnchor™ implants | 6.0 |
| Average total procedural time9 | 143.7 min |
| Average total fluoro time | 35.1 min |
| ANCHOR primary AAA arm (N = 771) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Type Ia endoleak | 2.5% (14/568) |
1.7% (6/346) |
2.9% (7/238) |
3.2% (5/154) |
4.8% (4/84) |
| Migration | 0.0% (0/368) |
0.0% (0/180) |
0.0% (0/114) |
0.0% (0/72) |
0.0% (0/37) |
Strong five-year sac regression in hostile necks
ANCHOR five-year results demonstrate durable, reinforced proximal seal
Revision AAA arm (n = 261)11
| ANCHOR revision AAA arm | N = 261 |
|---|---|
| Female | 15.3% |
| Average age | 77.8 years |
| Hostile necks | 88.7% (188/212) |
| ASA Class III/IV | 89.2% |
| Urgent or emergent | 23.8% (58/244) |
| ANCHOR revision AAA arm | N = 261 |
|---|---|
| Technical success | 95% |
| Average time to place EndoAnchor™ implants | 25.2 min |
| Average number of EndoAnchor™ implants | 7.4 |
| Average total procedural time | 145.5 min |
| Average total fluoro time | 32.5 min |
(For 4.6 years, see reference 12.)
| ANCHOR revision AAA arm (N = 261) | Year 5 |
|---|---|
| Type Ia endoleak9 | 3.7% (1/27) |
| Sac regressing or stable11 | 65.4% (17/26) |
| Sac regressing11 | 38.5% (10/26) |
| Migration9 | 0.0% (0/16) |
Five-year revision results over nine years post-index EVAR
Even in failed EVARs, ESAR delivers durability
Short neck cohort (n = 70)13
| ANCHOR short neck cohort | N = 70 |
|---|---|
| Female | 27% |
| Average age | 71 years |
| Hostile necks | 100% |
| ASA Class III/IV | 93% |
| Urgent or emergent | 31% |
| ANCHOR short neck cohort | N = 70 |
|---|---|
| Overall procedural success | 97.1% |
| Successful and accurate deployment of EndoAnchor implants14 | 92.9% |
| Average time to place EndoAnchor implants | 17.1 min |
| Average number of EndoAnchor implants | 5.5 |
| Average total procedural time | 148 min |
| Average total fluoro time | 35.5 min |
| ANCHOR short neck cohort (N = 70) | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Type Ia endoleak | 2.0% (1/51) |
2.7% (1/37) |
6.5% (2/31) |
| Sac regressing or stable | 100% (53/53) |
97.3% (36/37) |
93.7% (30/32) |
| Sac regressing | 35.8% (19/53) |
54.1% (20/37) |
46.9% (15/32) |
| Migration | 0 migrations at any time point |
||
Durable results, minimal reinterventions
Short neck cohort three-year results demonstrate strong outcomes and minimal reinterventions in hostile neck patients
TM* Third-party brands are trademarks of their respective owners.
† Wide neck definition varied from ≥ 25 mm to ≥ 31 mm.
‡ Denominator is the number of subjects with maximum aneurysm diameter reported at both the 1-month post implantation measurement and three-year follow-up time points.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.